USA flag logo/image

An Official Website of the United States Government

A Novel Polymeric Trileaflet Heart Valve Prosthesis

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
71013 		Program Year/Program:
2004 / SBIR
Agency Tracking Number:
HL078049 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
ABIOMED, INC.
22 CHERRY HILL DRIVE DANVERS, MA 01923-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: A Novel Polymeric Trileaflet Heart Valve Prosthesis
Agency: HHS
Contract: 1R43HL078049-01
Award Amount: $99,870.00
 

Abstract:

DESCRIPTION (provided by applicant): The development of a durable, hemocompatible valve prosthesis is the long-term objective of this proposal. While heart valve prostheses have been used successfully since 1960, 10-year survival rates still range from 37-58%. Existing replacement valves are either mechanical or biological. Bioprostheses suffer from time dependent structural changes leading to valve failure, while mechanical valves are subject to thrombus deposition and subsequent complications resulting from emboli. A valve offering the hemocompatibility of bioprostheses and the durability of mechanical valves would provide a superior alternative to those currently approved for clinical use. ABIOMED's polyurethane trileaflet valve has demonstrated excellent durability and hemocompatibility in clinical evaluation of the AbioCor replacement heart. The goal of this Phase I project is the development of a trileaflet heart valve prosthesis with low trans-valve pressure loss. The proposed work involves adapting the existing 24mm ABIOMED valve design to the requirements of a smaller, 21mm prosthetic valve, which is the most frequently used size in replacement surgeries. This work also includes in vitro performance characterization and accelerated valve cycling, as well as computer simulation using a novel computational fluid dynamics package. In Phase II, the valve design will be optimized, and hemocompatibility will be assessed through in vivo animal experiments.

Principal Investigator:

Scott C. Corbett
9786461684
SCORBETT@ABIOMED.COM

Business Contact:


9787775410
Small Business Information at Submission:

ABIOMED, INC.
22 CHERRY HILL DRIVE DANVERS, MA 01923

EIN/Tax ID: 042743260
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No